Additional data made available concerning first trimester dolutegravir use
Researchers from the ENTIS Paris COCHIN Center (Centre Régional de Pharmacovigilance et d’information sur le médicament) at the Assistance Publique-Hopitaux de Paris have published national surveillance data of first-trimester exposure to dolutegravir, raltegravir or elvitegravir in pregnancy, adding to the growing body of evidence available for integrase strand transfer inhibitors. More information can be found here.